Thus, inhibition of TB-dependent cytotoxicity by specific blocking of the receptor-ligand-(NKG2D-ULPB2)-binding sites could be achieved partially by pre-incubation of IL-2-expanded NK cells (10–14 days) with anti-NKG2D mAbs (1 μg/ml, 20 min) following treatment with 1 and 10 μg/ml TBs. The gene discussed is KLRK1; the disease is tuberculosis.